BSX Boston Scientific Corp

  1. Stocks
  2. Healthcare
  3. NYSE: BSX

Price (delayed)

$37.03

Market cap

$53.02B

P/E Ratio

13.97

Dividend/share

N/A

EPS

$2.65

Enterprise value

$60.34B

Sector: Healthcare
Industry: Medical Devices
Website: https://www.bostonscientific.com/

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, ...

Highlights

BSX's quick ratio has surged by 124% year-on-year and by 8% since the previous quarter
The equity has soared by 60% YoY
The P/E is 85% below the 5-year quarterly average of 96.0 but 10% above the last 4 quarters average of 12.7
Boston Scientific's gross profit has decreased by 8% YoY and by 2% QoQ
The EPS has decreased by 7% from the previous quarter

Key stats

What are the main financial stats of BSX
Market
Shares outstanding
1.43B
Market cap
$53.02B
Enterprise value
$60.34B
Valuations
Price to earnings (P/E)
13.97
Price to book (P/B)
3.4
Price to sales (P/S)
5.24
EV/EBIT
1,138.45
EV/EBITDA
56.71
EV/Sales
5.97
Earnings
Revenue
$10.11B
EBIT
$53M
EBITDA
$1.06B
Free cash flow
$1.25B
Per share
EPS
$2.65
Free cash flow per share
$0.87
Book value per share
$10.88
Revenue per share
$7.06
TBVPS
$9.72
Balance sheet
Total assets
$30.85B
Total liabilities
$15.28B
Debt
$9.34B
Equity
$15.56B
Working capital
$2.86B
Liquidity
Debt to equity
0.6
Current ratio
1.87
Quick ratio
1.1
Net debt/EBITDA
6.87
Margins
EBITDA margin
10.5%
Gross margin
67.2%
Net margin
36.6%
Operating margin
0.8%
Efficiency
Return on assets
12%
Return on equity
25%
Return on invested capital
0.3%
Return on capital employed
0.2%
Return on sales
0.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BSX stock price

How has the Boston Scientific stock price performed over time
Intraday
-1.31%
1 week
1.93%
1 month
7.77%
1 year
-15.94%
YTD
3%
QTD
3%

Financial performance

How have Boston Scientific's revenue and profit performed over time
Revenue
$10.11B
Gross profit
$6.79B
Operating income
$80M
Net income
$3.7B
Gross margin
67.2%
Net margin
36.6%
Boston Scientific's operating income has plunged by 95% YoY and by 88% from the previous quarter
BSX's operating margin has dropped by 95% year-on-year and by 88% since the previous quarter
Boston Scientific's gross profit has decreased by 8% YoY and by 2% QoQ
Boston Scientific's net income has decreased by 7% QoQ

Growth

What is Boston Scientific's growth rate over time

Valuation

What is Boston Scientific stock price valuation
P/E
13.97
P/B
3.4
P/S
5.24
EV/EBIT
1,138.45
EV/EBITDA
56.71
EV/Sales
5.97
The P/E is 85% below the 5-year quarterly average of 96.0 but 10% above the last 4 quarters average of 12.7
The EPS has decreased by 7% from the previous quarter
The equity has soared by 60% YoY
The stock's price to book (P/B) is 32% less than its 5-year quarterly average of 5.0 and 6% less than its last 4 quarters average of 3.6
BSX's P/S is 14% above its 5-year quarterly average of 4.6 and 2.7% above its last 4 quarters average of 5.1
The revenue has decreased by 2.7% YoY

Efficiency

How efficient is Boston Scientific business performance
The return on assets has surged by 167% year-on-year but it has declined by 11% since the previous quarter
The return on equity has surged by 112% year-on-year but it has declined by 17% since the previous quarter
BSX's ROIC has plunged by 97% YoY and by 86% from the previous quarter
The ROS has plunged by 96% YoY and by 86% from the previous quarter

Dividends

What is BSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BSX.

Financial health

How did Boston Scientific financials performed over time
Boston Scientific's total assets is 102% more than its total liabilities
BSX's quick ratio has surged by 124% year-on-year and by 8% since the previous quarter
Boston Scientific's debt is 40% lower than its equity
Boston Scientific's debt has decreased by 14% YoY and by 2.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.